Propafenone efficacy in paroxysmal atrial fibrillation
Efficacy and safety of class IС antiarrhythmic agent, propafenone, was investigated in patients with paroxysmal atrial fibrillation (PAF), after single-dose load and during long-term preventive treatment. The study included 20 male and female patients (mean age 53,8+2,4 years). PAF was caused by cor...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2004-12-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/2328 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849341021267165184 |
|---|---|
| author | V. V. Skibitsky E. A. Kudryashov N. A. Spiropulos A. M. Kramskaya Z. T. Sokaeva |
| author_facet | V. V. Skibitsky E. A. Kudryashov N. A. Spiropulos A. M. Kramskaya Z. T. Sokaeva |
| author_sort | V. V. Skibitsky |
| collection | DOAJ |
| description | Efficacy and safety of class IС antiarrhythmic agent, propafenone, was investigated in patients with paroxysmal atrial fibrillation (PAF), after single-dose load and during long-term preventive treatment. The study included 20 male and female patients (mean age 53,8+2,4 years). PAF was caused by coronary heart disease (CRT)) and/or essential arterial hypertension. For terminating PAF, a single dose of propafenone, 600 mg, was used. In 75% of cases, the medication was effective. In one patient (6%), long PW, wide QRS, and sinus rhythm deceleration to 48 bpm were observed. These symptoms disappeared without any additional therapy, 4 hours after sinus rhythm being restored. All patients with restored sinus rhythm received 6-month preventive treatment with propafenone (450 mg/d). In 9 patients (60%), there were no recurrent PAF episodes, in 4 (27%) - one PAF episode was registered, in 2 (13%), with BP higher than target levels - two PAF episodes. Extra-cardiac adverse effects of propafenone were not observed. Therefore, propafenone can be regarded as an effective and safe first-line medication for treating PAF. Long-term therapy, together with antianginal and antihypertensive treatment, significantly decreased the number of recurrent arrhythmic episodes. |
| format | Article |
| id | doaj-art-950ca427fcca496db89f8f7c4b516d49 |
| institution | Kabale University |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| publishDate | 2004-12-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj-art-950ca427fcca496db89f8f7c4b516d492025-08-20T03:43:44Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202004-12-010668702074Propafenone efficacy in paroxysmal atrial fibrillationV. V. Skibitsky0E. A. Kudryashov1N. A. Spiropulos2A. M. Kramskaya3Z. T. Sokaeva4Кубанская государственная медицинская академия; больница скорой медицинской помощиКубанская государственная медицинская академия; больница скорой медицинской помощиКубанская государственная медицинская академия; больница скорой медицинской помощиКубанская государственная медицинская академия; больница скорой медицинской помощиКубанская государственная медицинская академия; больница скорой медицинской помощиEfficacy and safety of class IС antiarrhythmic agent, propafenone, was investigated in patients with paroxysmal atrial fibrillation (PAF), after single-dose load and during long-term preventive treatment. The study included 20 male and female patients (mean age 53,8+2,4 years). PAF was caused by coronary heart disease (CRT)) and/or essential arterial hypertension. For terminating PAF, a single dose of propafenone, 600 mg, was used. In 75% of cases, the medication was effective. In one patient (6%), long PW, wide QRS, and sinus rhythm deceleration to 48 bpm were observed. These symptoms disappeared without any additional therapy, 4 hours after sinus rhythm being restored. All patients with restored sinus rhythm received 6-month preventive treatment with propafenone (450 mg/d). In 9 patients (60%), there were no recurrent PAF episodes, in 4 (27%) - one PAF episode was registered, in 2 (13%), with BP higher than target levels - two PAF episodes. Extra-cardiac adverse effects of propafenone were not observed. Therefore, propafenone can be regarded as an effective and safe first-line medication for treating PAF. Long-term therapy, together with antianginal and antihypertensive treatment, significantly decreased the number of recurrent arrhythmic episodes.https://russjcardiol.elpub.ru/jour/article/view/2328antiarrhythmicspropafenoneparoxysmal atrial fibrillationpreventive therapy |
| spellingShingle | V. V. Skibitsky E. A. Kudryashov N. A. Spiropulos A. M. Kramskaya Z. T. Sokaeva Propafenone efficacy in paroxysmal atrial fibrillation Российский кардиологический журнал antiarrhythmics propafenone paroxysmal atrial fibrillation preventive therapy |
| title | Propafenone efficacy in paroxysmal atrial fibrillation |
| title_full | Propafenone efficacy in paroxysmal atrial fibrillation |
| title_fullStr | Propafenone efficacy in paroxysmal atrial fibrillation |
| title_full_unstemmed | Propafenone efficacy in paroxysmal atrial fibrillation |
| title_short | Propafenone efficacy in paroxysmal atrial fibrillation |
| title_sort | propafenone efficacy in paroxysmal atrial fibrillation |
| topic | antiarrhythmics propafenone paroxysmal atrial fibrillation preventive therapy |
| url | https://russjcardiol.elpub.ru/jour/article/view/2328 |
| work_keys_str_mv | AT vvskibitsky propafenoneefficacyinparoxysmalatrialfibrillation AT eakudryashov propafenoneefficacyinparoxysmalatrialfibrillation AT naspiropulos propafenoneefficacyinparoxysmalatrialfibrillation AT amkramskaya propafenoneefficacyinparoxysmalatrialfibrillation AT ztsokaeva propafenoneefficacyinparoxysmalatrialfibrillation |